288 related articles for article (PubMed ID: 25294906)
1. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract][Full Text] [Related]
2. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
4. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
[TBL] [Abstract][Full Text] [Related]
5. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer.
Ehlers M; Kuebart A; Hautzel H; Enczmann J; Reis AC; Haase M; Allelein S; Dringenberg T; Schmid C; Schott M
J Clin Endocrinol Metab; 2017 Jul; 102(7):2154-2161. PubMed ID: 27860539
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
[TBL] [Abstract][Full Text] [Related]
7. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
[TBL] [Abstract][Full Text] [Related]
8. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
9. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
10. Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.
Cunha LL; Nonogaki S; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2017 Dec; 28(4):369-372. PubMed ID: 28730569
[TBL] [Abstract][Full Text] [Related]
11. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
12. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
14. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
16. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
17. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
18. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter.
Yu H; Huang X; Liu X; Jin H; Zhang G; Zhang Q; Yu J
Endocrine; 2013 Aug; 44(1):172-81. PubMed ID: 23264145
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
